| Document |
Document Title |
|
WO/2022/125636A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/120226A1 |
The present disclosure provides methods and related compositions that incorporate a molecularly targeted approach via the integrin subtype αvβ6 using Peptide Receptor Radionuclide Therapy (PRRT) and a theranostic approach.
|
|
WO/2022/115973A1 |
Disclosed are methods for precipitation of CBDA-amine salts and THCA-amine salts from concentrated crude complex extracts. The crude complex extracts may be recovered from cannabis biomass or fermentation systems wherein microorganisms w...
|
|
WO/2022/116714A1 |
Provided in the present application are a compound and the medical use thereof for novel coronavirus pneumonia, which belongs to the technical field of pharmaceuticals. The compound is a compound represented by formula I or formula II, o...
|
|
WO/2022/115326A1 |
Described herein are methods of making the PPARδ agonist compound (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-
yl)phenyl)allyl)oxy)-2-methylphenoxy)acetic acid, including salt forms thereof.
|
|
WO/2022/112855A1 |
A lipid compound of formula (I), including lipid nanoparticles thereof, and the manufacturing method and the use of pharmaceutical delivery are provided. The lipid compounds have formula (I): or a salt or an isomer thereof, wherein R1, R...
|
|
WO/2022/115439A1 |
The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and ar...
|
|
WO/2022/107463A1 |
One objective of the present invention is to provide a novel method for producing a ketone derivative. Provided is a method for producing a ketone derivative (I) represented by formula (I), the method comprising a step for forming a keto...
|
|
WO/2022/105046A1 |
Provided is a synthesis method of trans-4-[4-(3-methoxy-4-nitrophenyl)-1-piperazinyl]adamantan
e-1-ol. The method comprises: taking 2-nitro-5-fluoroanisole as the starting raw material, and subjecting same to a three-step nucleophilic su...
|
|
WO/2022/095461A1 |
Disclosed are a compound for specifically enhancing the spatial coupling degree of a TRPV4-KCa2.3 complex and the use thereof, which belong to the field of chemical medicines. The compound, which has a structure of general formula (I), m...
|
|
WO/2022/093610A1 |
Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl)phenyl)naphthalene-
1-sulfonamide dihydrochloride dihydrate, methods of preparing the crystalline salt, pharmaceutical compositions containing the crystalline salt, and methods of trea...
|
|
WO/2022/093780A1 |
Methods to activate or enhance phosphorylation of focal adhesion kinase (FAK) are provided herein. Methods to treat epithelial disorders in mammals, namely diseases of the gut, comprising the administration of one or more small molecules...
|
|
WO/2022/084254A1 |
The present invention describes a mixture of isomeric aldimines of the formulae (Ia), (Ib) and (Ic) in which the ratio of the trans,trans isomer (Ia) to the sum of the cis,trans isomer (Ib) and the cis,cis isomer (Ic) is in the range of ...
|
|
WO/2022/087008A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2022/086894A1 |
The present disclosure encompasses solid state forms of Resmetirom, in embodiments crystalline polymorphs of Resmetirom, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2022/078306A1 |
The present invention relates to the technical field of organic synthesis and chemical catalysis. Disclosed are a large steric hinderance palladium-nitrogen-heterocyclic carbene complex, a preparation method for same, applications of sam...
|
|
WO/2022/072504A1 |
The present disclosure relates to antiviral composition and methods. Methods for using the antiviral compositions of the disclosure for inhibiting the growth of viruses and treatment of viral diseases are also described.
|
|
WO/2022/059700A1 |
The present invention provides a triazine compound salt that has an aldosterone synthase inhibitory effect and is useful as a medicine, in particular, an agent for preventing or treating primary aldosteronism and the like, a crystal, and...
|
|
WO/2022/056737A1 |
A synthetic method for a Venetoclax intermediate and analogues thereof. The reaction formula is as follows, where Y is a carbon atom or a nitrogen atom, R is a hydrogen atom or an organic substituent group, M is an alkali metal, alkaline...
|
|
WO/2022/060459A1 |
Organic compounds for target identification, drug discovery, chemical library production, high-throughput screening, fluorophore conjugation, chemiluminescent compound conjugation, creation of proximity induced modulators (e.g., protein ...
|
|
WO/2022/059684A1 |
Provided is a vitamin D derivative demonstrating excellent central nervous system migration, or a pharmaceutically acceptable salt or a solvate thereof. Specifically provided is a vitamin D derivative represented by formula (1), or a p...
|
|
WO/2022/051862A1 |
The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and/or Formula (VI) as defined h...
|
|
WO/2022/052391A1 |
The present invention relates to a method for synthesizing vortioxetine or a pharmaceutically acceptable salt thereof. The process is accomplished by using a catalytic system consisting of a copper salt and an organic ligand. The catalyt...
|
|
WO/2022/054755A1 |
The present invention relates to providing a new method for easily detecting tumor cells in tissue from a living body. The present invention includes a fluorescent dye containing a compound that exhibits solvatochromism for detecting tum...
|
|
WO/2022/051804A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides. Formula (A)
|
|
WO/2022/051565A1 |
The invention provides substituted 4-piperidinyl-quinazolines, 4-piperidinyl-pyrimidine-2-amines, and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disor...
|
|
WO/2022/045175A1 |
A purpose of the present invention is to provide a compound useful as a co-catalyst to be used in polymerization reactions of olefins, dienes, and acetylenes. According to the present invention, a fluorine-containing alkyl ammonium borat...
|
|
WO/2022/042643A1 |
Disclosed are a pharmaceutically acceptable salt of cariprazine, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof. The pharmaceutically acceptable salt of cariprazine is a salt formed from ...
|
|
WO/2022/037465A1 |
The present invention relates to a lipid nanoparticle. The lipid nanoparticle is formed by a compound of the following structure (I) or pharmaceutically acceptable salt, tautomer or stereisomer thereof. The present invention also provide...
|
|
WO/2022/040395A2 |
Compounds, compositions, and methods are provided for dual partial agonism of serotonin 5-HT7 and 5-HT1A receptors. The enantiomerically pure 5-phenyl-2-aminotetralin (5-PAT) compounds can be used to treat or prevent substance use disord...
|
|
WO/2022/037590A1 |
The present invention relates to the field of medical chemistry and provides a quaternary ammonium salt compound for anesthesia, a preparation method therefor, and use thereof. The quaternary ammonium salt compound is a compound as repre...
|
|
WO/2022/039079A1 |
A fluorine-containing ether compound represented by formula (1). (1) R1-O-R2-CH2-R3-CH2-R4-R5 (in which R3 is a perfluoropolyether chain, R1 is a C2–8 alkenyl group or a C3–8 alkynyl group, R2 and R4 are each independently a bivalent...
|
|
WO/2022/035804A1 |
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof and pharmaceutical composition comprising the compound of formula (I). The present composition also relates to methods treating a d...
|
|
WO/2022/024928A1 |
The present invention addresses the problem of providing an actinic-ray-sensitive or radiation-sensitive resin composition capable of forming patterns having excellent LWR performance. Also provided are a resist film, a pattern formation...
|
|
WO/2022/025640A1 |
The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides ...
|
|
WO/2022/022612A1 |
The invention relates to novel glutamine analogs shown as the formula I, a composition containing the glutamine analogs and the use thereof.
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/020963A1 |
A method for the synthesis of specialized pro-resolving mediators, structural isomers thereof and analogs thereof is disclosed herein. The method comprises reacting a compound of the formula (I): (I) wherein R1 is alkyl(C≤12), cycloalk...
|
|
WO/2022/022846A1 |
The present invention relates to a compound of general formula (I) wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula (I) binds to VDAC1 and is suitable for use in a method for treating diabetes or pre- diabetes ...
|
|
WO/2022/020376A1 |
Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-
yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the...
|
|
WO/2022/013408A2 |
The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceuti...
|
|
WO/2022/014646A1 |
Provided is an amineimide compound having excellent permeability, excellent curability, and storage stability. An amineimide compound represented by formula (1), (2), or (3). (In formulae (1)-(3), R1s each independently represent a hydro...
|
|
WO/2022/011948A1 |
A preparation method for vortioxetine, comprising: reacting 2,4-dimethylthiophenol (compound IV) and o-difluorobenzene (compound V) to form a compound III, reacting said compound III with boc-piperazine to form a compound II, and deprote...
|
|
WO/2022/000443A1 |
Provided herein are compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
|
|
WO/2022/003181A1 |
The present invention relates to urea derivatives of polyene macrolides having the following chemical formula: wherein: - R1 is hydrogen or an alkyl or aryl or acyl group, and R2, independently of R1, is hydrogen or an alkyl or aryl or a...
|
|
WO/2021/262214A1 |
Embodiments of the present disclosure are directed to a method of making a reaction inhibiting polymer having a formula of M-CO-NR. The method may comprise reacting PAA with an organic coupling reagent and at least one alicyclic amine to...
|
|
WO/2021/255180A1 |
The present invention relates to 2-aminoethanol, piperazine and L- lysine salts of Bempedoic acid and processes for the preparation thereof.
|
|
WO/2021/251337A1 |
CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compo...
|
|
WO/2021/240295A1 |
The present invention relates to a process for the preparation of favipiravir and salts thereof. The present invention also relates to salts of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile with inorganic base, process for their preparation ...
|
|
WO/2021/241876A1 |
Disclosed are a carboxamide derivative and a pharmaceutical composition comprising same as an active ingredient for preventing or treating mental illness. The derivative is superbly effective as a triple reuptake inhibitor of serotonin, ...
|
